Skip to main content

Table 2 Latency and size of melanoma tumors after inoculation of B16 cells, preincubated or not with NeuGc-rich BSM.

From: Exogenous incorporation of neugc-rich mucin augments n-glycolyl sialic acid content and promotes malignant phenotype in mouse tumor cell lines

Treatment Tumor latencyA
(days)
Tumor DiameterA
(mm)
Tumor Growth RateA
(mm/day)
Control 12.8 ± 1.6 2.2 ± 0.9 0.15 ± 0.03
BSM-preincubated 8.4 ± 0.6** 7.1 ± 1.8* 0.18 ± 0.05
  1. ATumor latency represents the time between the subcutaneous injection of a small burden of B16 cells (5 × 103 cells/mouse) and the appearance of detectable tumors.
  2. Tumor diameter was recorded at day 35 after tumor cell inoculation. Values represent mean ± SEM of at least 8 mice.
  3. **p < 0.01 and *p < 0.05 (t test).